Patents by Inventor Jason S. Lewis
Jason S. Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240058482Abstract: This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.Type: ApplicationFiled: January 31, 2023Publication date: February 22, 2024Inventors: Gabriela Chiosis, Nagavarakishore Pillarsetty, Jason S. Lewis, Steven M. Larson, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-DaGama
-
Publication number: 20230372551Abstract: The present disclosure provides compounds, complexes, compositions, and methods for the detection of cancer. Specifically, the compounds, complexes, compositions of the present technology include pH (low) insertion peptides. Also disclosed herein are methods of using the complexes and compositions of the present technology in diagnostic imaging to detect cancer in a subject.Type: ApplicationFiled: September 21, 2021Publication date: November 23, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES, PHLIP, INC.Inventors: Jason S. LEWIS, Yana K. RESHETNYAK, Lukas M. CARTER, David BAUER
-
Publication number: 20230241259Abstract: The present technology is directed to compounds useful in the imaging of peripheral neurons.Type: ApplicationFiled: June 8, 2021Publication date: August 3, 2023Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Junior Gonzales, Javier Hernández-Gil, Jason S. Lewis, Thomas Reiner
-
Publication number: 20230158180Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: ApplicationFiled: July 5, 2022Publication date: May 25, 2023Inventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Patent number: 11607465Abstract: This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.Type: GrantFiled: July 21, 2020Date of Patent: March 21, 2023Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gabriela Chiosis, Naga Vara Kishore Pillarsetty, Jason S. Lewis, Steven M. Larson, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-DaGama
-
Publication number: 20220305149Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel radiohalogenated (e.g., radioiodinated) PSMA targeting agents and methods of using the same in diagnostic imaging as well as radiation therapy.Type: ApplicationFiled: August 28, 2020Publication date: September 29, 2022Inventors: Naga Vara Kishore PILLARSETTY, Teja Muralidhar KALIDINDI, Sang-Gyu LEE, Steven M. LARSON, Jason S. LEWIS, Serge LYASHCHENKO, Eva BURNAZI
-
Publication number: 20220275017Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.Type: ApplicationFiled: March 14, 2022Publication date: September 1, 2022Inventors: David Y. GIN, Eric K. CHEA, Alberto FERNANDEZ-TEJADA, Derek S. TAN, Jason S. LEWIS, Jeffrey R. GARDNER, NagaVaraKishore PILLARSETTY
-
Patent number: 11419955Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: GrantFiled: December 13, 2019Date of Patent: August 23, 2022Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Patent number: 11274116Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.Type: GrantFiled: April 20, 2020Date of Patent: March 15, 2022Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: David Y. Gin, Eric K. Chea, Alberto Fernandez-Tejada, Derek S. Tan, Jason S. Lewis, Jeffrey R. Gardner, NagaVarakishore Pillarsetty
-
Publication number: 20210283281Abstract: The present disclosure provides compounds, complexes, compositions, and methods for the detection of cancer. Specifically, the compounds, complexes, compositions of the present technology include pH (low) insertion peptides. Also disclosed herein are methods of using the complexes and compositions of the present technology in diagnostic imaging to detect cancer in a subject.Type: ApplicationFiled: July 29, 2017Publication date: September 16, 2021Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, RHODE ISLAND COUNCIL ON POSTSECONDARY EDUCATION, PHLIP, INC.Inventors: Jason S. LEWIS, Dustin DEMOIN, Yana K. RESHETNYAK, Oleg A. ANDREEV, Donald M. ENGELMAN, Narissa VIOLA-VILLEGAS
-
Publication number: 20210138091Abstract: This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.Type: ApplicationFiled: July 21, 2020Publication date: May 13, 2021Inventors: Gabriela Chiosis, Naga Vara Kishore Pillarsetty, Jason S. Lewis, Steven M. Larson, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-DaGama
-
Publication number: 20210070796Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.Type: ApplicationFiled: April 20, 2020Publication date: March 11, 2021Inventors: David Y. Gin, Eric K. Chea, Alberto Fernandez-Tejada, Derek S. Tan, Jason S. Lewis, Jeffrey R. Gardner, NagaVaraKishore Pillarsetty
-
Publication number: 20200376149Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: ApplicationFiled: December 13, 2019Publication date: December 3, 2020Inventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Patent number: 10821195Abstract: Described herein is a chelator for radiolabels (e.g., 89Zr) for targeted PET imaging that is an alternative to DFO. In certain embodiments, the chelator for 89Zr is the ligand, 3,4,3-(LI-1,2-HOPO) (“HOPO”), which exhibits equal or superior stability compared to DFO in chemical and biological assays across a period of several days in vivo. As shown in FIG. 1, the HOPO is an octadentate chelator that stabilizes chelation of radiolabels (e.g., 89Zr). A bifunctional ligand comprising p-SCN-Bn-HOPO is shown in FIG. 4 and FIG. 5. Such a bifunctional ligand can eliminate (e.g., 89Zr) loss from the chelate in vivo and reduce uptake in bone and non-target tissue. Therefore, the bifunctional HOPO ligand can facilitate safer and improved PET imaging with radiolabeled antibodies.Type: GrantFiled: September 9, 2016Date of Patent: November 3, 2020Assignees: Memorial Sloan Kettering Cancer Center, Research Foundation of the City University of New YorkInventors: Jason S. Lewis, Melissa Deri, Lynn Francesconi, Shashikanth Ponnala
-
Publication number: 20200206369Abstract: Presented herein are methods and compositions for non-invasive imaging of TAMs with discoidal high-density lipoproteins to assess prognosis and therapy outcome. TAMs are increasingly investigated in cancer immunology, and are considered a promising target for better and tailored treatment of malignant growths. Although TAMs also have high diagnostic and prognostic value, TAM imaging still remains largely unexplored. Imaging agents/methods provided herein are of value for non-invasive in vivo evaluation of TAM burden, not only in preclinical but also in clinical settings.Type: ApplicationFiled: December 5, 2019Publication date: July 2, 2020Applicant: Memorial Sloan Kettering Cancer CenterInventors: Carlos PEREZ-MEDINA, Thomas REINER, Jason S. LEWIS, Willem MULDER, Zahi FAYAD, Edward FISHER
-
Patent number: 10626137Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.Type: GrantFiled: June 1, 2015Date of Patent: April 21, 2020Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: David Y. Gin, Eric K. Chea, Alberto Fernandez-Tejada, Derek S. Tan, Jason S. Lewis, Jeffrey R. Gardner, NagaVaraKishore Pillarsetty
-
Patent number: 10548997Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: GrantFiled: March 1, 2017Date of Patent: February 4, 2020Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Hooisweng Ow, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Patent number: 10548998Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: GrantFiled: June 15, 2018Date of Patent: February 4, 2020Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Patent number: 10512700Abstract: Disclosed are chemical entities of formula (I) wherein R1, R2 and n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1 is overexpressed.Type: GrantFiled: August 27, 2015Date of Patent: December 24, 2019Assignee: Memorial Sloan Kettering Cancer CenterInventors: Thomas Reiner, Jason S. Lewis, Wolfgang Weber, Beatriz Salinas Rodriguez, Brandon Carney, Giuseppe Carlucci
-
Publication number: 20190298864Abstract: Described herein is a chelator for radiolabels (e.g., 89Zr) for targeted PET imaging that is an alternative to DFO. In certain embodiments, the chelator for 89Zr is the ligand, 3,4,3-(LI-1,2-HOPO) (“HOPO”), which exhibits equal or superior stability compared to DFO in chemical and biological assays across a period of several days in vivo. As shown in FIG. 1, the HOPO is an octadentate chelator that stabilizes chelation of radiolabels (e.g., 89Zr). A bifunctional ligand comprising p-SCN-Bn-HOPO is shown in FIG. 4 and FIG. 5. Such a bifunctional ligand can eliminate (e.g., 89Zr) loss from the chelate in vivo and reduce uptake in bone and non-target tissue. Therefore, the bifunctional HOPO ligand can facilitate safer and improved PET imaging with radiolabeled antibodies.Type: ApplicationFiled: September 9, 2016Publication date: October 3, 2019Applicants: Memorial Sloan Kettering Cancer Center, Research Foundation of the City University of New YorkInventors: Jason S. Lewis, Melissa Deri, Lynn Francesconi, Shashikanth Ponnala